BTG, the specialist healthcare company, said it had outperformed in the first half and was boosting its revenue expectations for the full year.
The firm said is raising its revenue estimate for the year ending March 31st 2013 from £190m-£200m to £205m-£215m after a strong first half performance and a positive outlook for the second.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It also saw a strong start from post-chemotherapy drug Voraxaze following its US nationwide launch at the end of April 2012
Among other products, it also noted the continued growth of royalties from Johnson & Johnson's prostate cancer drug Zytig.
First half revenue also included £5.4m of additional deferred income relating to a previous licence agreement that had been fully following AstraZeneca's decision axe development of CytoFab, nn experimental treatment for severe sepsis that failed in trials.
-
Norfolk or Norway? Holidays you can afford with different-sized pension potsMany people look forward to taking more holidays when they retire. But what sort of trips could your pension buy you? We look at the holidays to match different retirement incomes
-
Q&A: Issac Thong – new lead manager of Aberdeen Asian Income Fund
